Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Inclisiran (Leqvio) vs Rosuvastatin (Crestor): they're closely matched on evidence (4.1 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Inclisiran (Leqvio) and Rosuvastatin (Crestor) are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Inclisiran (Leqvio) and Rosuvastatin (Crestor) have evidence — compare verdict strength side-by-side.
284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.
any
Prefilled subcutaneous injection (inclisiran 284 mg)
5–20 mg once daily (up to 40 mg in selected high-risk patients), titrated to LDL/ApoB targets — under a clinician. A prescription drug; not a self-directed supplement regimen.
any
Oral tablet (rosuvastatin 5–20 mg)
Weeks to months; sustained
Ongoing
Outcomes trials ongoing
Around each injection
2–4 weeks
Months to years
1–2 years
Throughout use
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
The New England journal of medicine (2020) · Rct · n=3178
ORION-10 and ORION-11 randomized, placebo-controlled phase 3 trials in atherosclerotic cardiovascular disease / high risk
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
The New England journal of medicine (2020) · Rct · n=482
ORION-9 randomized, placebo-controlled phase 3 trial in heterozygous familial hypercholesterolemia
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
The New England journal of medicine (2017) · Rct · n=501
ORION-1 phase 2, double-blind, placebo-controlled, multiple-ascending-dose trial
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
The New England journal of medicine (2008) · Rct · n=17802
JUPITER randomized placebo-controlled primary-prevention trial (~17,800 participants with normal LDL but elevated hsCRP)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet (London, England) (2010) · Meta analysis
Meta-analysis of ~170,000 participants across 26 randomized statin trials
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
JAMA (2006) · Open label · n=507
ASTEROID open-label IVUS trial (507 enrolled; 349 with evaluable serial imaging)
Both Inclisiran (Leqvio) and Rosuvastatin (Crestor) are closely matched — the best choice depends on your specific health goals.
For support heart health, Rosuvastatin (Crestor) has a higher relevance score (78 vs 70).
No known interactions between Inclisiran (Leqvio) and Rosuvastatin (Crestor) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.